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Abstract
Background: Over the last decades numerous initiatives have been set up that aim at translating the best available
medical knowledge and treatment into clinical practice. The inherent complexity of the programs and discrepancies
in the terminology used make it difficult to appreciate each of them distinctly and compare their specific strengths
and weaknesses. To allow comparison and stimulate dialogue between different programs, we in this paper provide
an overview of the German Cancer Society certification program for multidisciplinary cancer centers that was
established in 2003.
Main body: In the early 2000s the German Cancer Society assessed the available information on quality of cancer
care in Germany and concluded that there was a definite need for a comprehensive, transparent and evidence-
based system of quality assessment and control. This prompted the development and implementation of a
voluntary cancer center certification program that was promoted by scientific societies, health-care providers, and
patient advocacy groups and based on guidelines of the highest quality level (S3). The certification system
structures the entire process of care from prevention to screening and multidisciplinary treatment of cancer and
places multidisciplinary teams at the heart of this program. Within each network of providers, the quality of care is
documented using tumor-specific quality indicators. The system started with breast cancer centers in 2003 and
colorectal cancer centers in 2006. In 2017, certification systems are established for the majority of cancers. Here we
describe the rationale behind the certification program, its history, the development of the certification
requirements, the process of data collection, and the certification process as an example for the successful
implementation of a voluntary but powerful system to ensure and improve quality of cancer care.
Conclusion: Since 2003, over 1 million patients had their primary tumors treated in a certified center. There are
now over 1200 sites for different tumor entities in four countries that have been certified in accordance with the
program and transparently report their results from multidisciplinary treatment for a substantial proportion of
cancers. This led to a fundamental change in the structure of cancer care in Germany and neighboring countries
within one decade.
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Background
In addition to breakthroughs that have been made in the
diagnosis and treatment of cancers, considerable effort
over the last 20 years has been put into ensuring that
the state of the art of care is translated into everyday
care for the entire population in need. Indeed, this issue
is at the heart of the debate about the quality of cancer
care and how to improve it [1–5]. Numerous campaigns
have been initiated that aim at translating the best
available medical knowledge and treatment into clinical
practice. They typically define standards for how to
measure, compare, and improve the quality of care and
how to best incorporate multidisciplinarity [6–12].
Some initiatives have also developed certification and
accreditation programs for quality assurance and quality
development using rigorous data collection processes,
quality indicators, on-site auditing and peer review.
These campaigns are partly government-driven, but
most have been initiated by professional associations
[12–16]. The inherent complexity of the programs and
discrepancies in the terminology used make it difficult
to appreciate each of them distinctly and compare their
specific strengths and weaknesses. To allow comparison
and stimulate dialogue between different programs, we
describe here the certification system organized by the
German Cancer Society (Deutsche Krebsgesellschaft,
DKG). We explain the rationale for the certification pro-
gram, the development of the certification requirements,
the process of data collection, and the certification
process.
Discussion
Rationale and brief history of the program
In the early 2000s, analyses of the limited data available
suggested that despite enormous financial resources the
results regarding cancer survival in Germany were only
moderate compared to the results obtained in other
European countries [17]. This resulted in several initia-
tives aimed at improving care, such as the development
of clinical guidelines of the highest quality level for the
most frequent cancer entities and a novel Cancer Center
Certification Program by the DKG. This program was
initially introduced for breast cancer following the
example of the EUSOMA effort (European Society of
Breast Cancer Specialists, [14, 18]) and soon afterwards
also for other types of cancer. The program was
intended to put evidence-based guideline recommenda-
tions into practice in everyday care and to place multi-
disciplinary teams at the heart of the cancer care
process. To ensure that evidence-based standards are
met in the certified units an auditing system based on
quality metrics was implemented. The Cancer Center
Certification Program was originally initiated, and has
since been continually developed, by the professional as-
sociations involved in cancer care, working groups, and
patient advocacy groups. Participation in the certifica-
tion system is voluntary. This means that there is no of-
ficial (government) body that requests certification in
order to be able to provide a particular cancer service,
and the government is not involved in defining the
criteria for certification.
The centers established within the DKG certification
system are tumor-specific networks (for an overview of
the various types of center, see Fig. 1) in which patients
are treated in a comprehensive, interdisciplinary, and
multi-professional manner. Disciplines that are essential
for the treatment of a particular cancer are specifically
defined for each type of center. In breast cancer centers
for example these teams comprise gynecologists, radiolo-
gists, pathologists, medical oncologists, radiotherapists,
and specialists in nuclear medicine (termed “main
cooperation partners”). In addition, written agreements
for on request services have to be made with representa-
tives of the following fields: oncological nursing, psycho-
oncology, hospice/palliative medicine, social services,
patient advocacy groups, genetic counseling, physio-
therapy, laboratory medicine, and supplier of medical
products [19].
Development of the DKG cancer centers in Germany
Shortly after the publication of the first Eurocare results
[17], the DKG and the German Society for Breast
A Comprehensive Cancer Center (CCC) is a leading oncology center with  
major research aims. Specifically for rarercancers and special issues
An Oncology Center extends to several organs or specialties, 
particularly for less common cancers such as neurological,  
head and neck, pancreatic, liver, and stomach cancer
An Organ Cancer Center is a center specializing 
in one organ or specialty (breast, colorectal,
lung, prostate, skin, gynecological tumors)
Fig. 1 The three-tier model of certified cancer centers
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Diseases (Deutsche Gesellschaft für Senologie, DGS)
established the first set of criteria for certified cancer
centers in accordance with the national clinical guide-
lines for breast cancer [20]. Subsequently, colorectal
cancer centers (2006), skin cancer centers, gynecological
cancer centers, lung cancer centers, and prostate cancer
centers (all in 2008) were added to the certification
program, each following guidelines of the highest quality
level for the respective cancer entity. Each program has
overlapping, general standards but also contains a set of
distinct, cancer-specific requirements. Some of these
requirements are translated into quality metrics that
allow for comparisons across the different sites all over
the country. The centers cover the whole spectrum of
care for the respective tumor including prevention, early
detection, treatment of the primary and advanced
tumors, supportive and palliative care as well as psy-
chooncology, social support and self-help groups.
Fig. 2 Numbers of center sites, 2003–2016
Table 1 Current status of the certification system
Organ cancer centers Modules Oncology
centers
Comprehensive







4 7 6 5 5 7 6 8 5 6
Certified center 230 280 133 55 45 103 41 26 91 97
Certified center sites 280 288 135 55 53 104 43 27 93 109 15
Primary cases, 2015 54,230 26,660 12,306 11,209b 17,731 19,932 6273c 5456d 4070 35,670
New cases of
cancera
70,170 62,230 26,140 20,820
b
52,520 63,710 15,628c – 16,730 –
Total sharee 74.6% 41.4% 43.6% 50.8% 32.9% 29.6% 37.5% – 22.9% –
Center sites abroad 11 10 9 4 2 7 4 1 6 6
CNS, central nervous system
aBased on German registry data from 2012
bOnly includes malignant melanoma
cNew cases of head and neck tumor: mouth and pharynx ICD-10 C00–C06, C09–C14, larynx C32
dNeuroendocrine tumors (C70–C75, in the International Classification of Diseases for Oncology, ICD-O)
eNumerator: primary patients from centers in Germany, denominator: primary cases in Germany
As of: 31 December 2016, does not include data on the two most recently added modules (liver, stomach)
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The DKG program operates as part of the German
National Cancer Plan led by the German Ministry of
Health [21], that laid down a three-tier model of cancer
centers in Germany consisting of Organ Cancer Centers
(C), Oncology Centers (CC), and Comprehensive Cancer
Centers (CCC, funded by the German Cancer Aid) (Fig. 1)
[22]. Patient care must meet the same quality require-
ments in all aspects irrespectively of the institution and of
its position in the three-tier model of the National Cancer
Certification Program [23].
As of January 2017, there are 1200 certified Organ Can-
cer Centers, 109 Oncology Centers, and 15 Comprehensive
Cancer Centers in Germany. Fig 2 demonstrates that this
still entirely voluntary program is continuously growing. By
now, approximately 40% of the population in Germany
with primary cancers for which centers have been estab-
lished are treated in certified institutions (Table 1). The
geographic distribution of centers is illustrated in Fig. 3.
Sixty sites are currently located in countries neighboring
Germany — Italy, Switzerland, and Austria.
Certification: Structure, standards, and fulfillment
To provide the greatest possible degree of professional
independence for those who develop and review the
requirements and their implementation, and to avoid
individual conflicts of interest, the certification system is
Fig. 3 The distribution of centers in Germany
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divided into three branches that work independently of
each other (Fig. 4 “Separation of Powers”).
1. The cancer type–specific Certification Committee
(corresponding to a “legislative” body): This
committee defines and develops the requirements
specification for the certification of the respective
centers based on evidence-based clinical guidelines
of the highest quality (S3 level, with S standing for
“Stufenklassifikation” or “step classification”) and
supplemented by recent research results that are not
yet part of the guidelines or refer to structural
requirements e.g., staffing or technical infrastructure.
The clinical guideline categories as defined by the
German Association of the Scientific Medical
Societies (AWMF) range from S1 to S3, with S1
being based on expert consensus only and S3 (the
highest level) being evidence based, i.e. based on a
systematic literature review following defined
criteria; having a representative guideline panel
including patients; and using a formal consensus
finding process. Based on the core recommendations
of the guidelines, quality indicators are derived and
implemented into the certification requirements
[24]. Recent research results and structural
requirements, unless suggested by clinical guidelines,
are based on expert consensus in the respective Cer-
tification Committee, allowing for example patients
to suggest requirements that are then discussed.
Each cancer–specific Certification Committee con-
sists of 30–40 experts of all specialties and professional
groups involved that have been delegated by their re-
spective professional medical society, by scientific so-
cieties, working groups, and self-help organizations.
The Certification Committees convene annually or
biennially to discuss the results from the certified cen-
ters and ensure timely updates of the requirements
specification.
2. Audit and data evaluation (corresponding to an
“executive” body): To obtain the certificate for a
specific cancer center the applicants must comply
with the standards set out in the requirements
specification developed by the relevant Certification
Committee of the DKG. Data on the requirements
are documented by each center using an electronic
reporting system. Data are then reported to an
independent certification institute, OnkoZert,
where the documentation is formally checked for
completeness and plausibility. To assure
independence, OnkoZert manages the documents,
organizes the audits and commissions the auditors
but cannot influence the decision of awarding the
certificate. Specially trained oncological medical
experts from various specialties including surgery,
pathology, gastroenterology, medical oncology,
gynecology (i.e., the auditors) verify the
implementation of the requirements and the validity
of the documentation. Verification of the
implementation of the requirements is done during
an on-site audit of the documentation, of structures
and processes at the centers. During these audits,
the auditors examine actual patient files and discuss
the results with the centers at the end of the site
visit. The auditors prepare a written report about the
data and the on-site visit. If any non-compliance
with the certification requirements is observed
during the audit, the auditor pronounces a so-called
“deviation”. The center then has three months to
remedy this deviation starting from the audit day.
Positive remedying is the precondition for the
award of the certificate. The auditors include a
recommendation about the award of a certificate in
their report. If the center fails to remedy a deviation,
the auditor will recommend to not issue the
certificate. Auditors must not be members of the
Certification Committee.
3. Certificate Award Committee (corresponding
to "jurisdiction"): The final decision whether to
award or deny a certificate is taken by another
independent body, the Certificate Award Committee.
This committee consists of three medical experts
who are not involved in the corresponding audit.
The Committee awards or denies the certificates
based on the audit report and the auditors’
recommendations. In 2016, 117 new certificates
have been awarded and 14 certificates have been
withdrawn because of not sufficient audit results.
Data reporting
All data from the tumor documentation of the respective
centers are submitted electronically to the independent















Fig. 4 The separation of powers in the certification system
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Table 2 Example quality indicators for each center/module type
Center/
module
Quality indicator definition Target value Sites meeting the
target in 2015
Median Source
Breast Pretreatment histological confirmation
(numerator: patients with pretreatment
histological diagnosis confirmation by
means of a punch or vacuum biopsy;
population: patients with initial procedure
and histology showing invasive breast
cancer or DCIS as primary disease)
≥ 90% 97.5% (268/275) 97.6% Annual Report of Certified Breast
Cancer Centers 2016 —Quality
Indicators (in English)
doi:10.13140/RG.2.1.1805.7204
Colorectal Quality of the TME rectum specimen
(information from pathology; numerator:
patients with good to moderate quality
TME [grade 1: mesorectal fascia or grade 2:
intramesorectal excisions]; population:
patients with radically operated rectal
cancer)
≥ 70% 98.5% (257/261) 95.2% Annual Report of Certified Colorectal
Cancer Centers 2016 — Quality
Indicators (in English)
doi:10.13140/RG.2.1.3771.8001
Prostate Percutaneous radiotherapy with hormone
ablation therapy for locally confined
prostate carcinoma with high risk
(numerator: primary cases with additional
neoadjuvant and/or adjuvant hormone
ablation therapy; population: primary cases
with prostate carcinoma T1–2 N0 M0 with
high risk (PSA > 20 ng/mL or Gleason






Annual Report of Certified Prostate
Cancer Centers 2016 — Quality
Indicators (in English)
doi:10.13140/RG.2.1.3673.4969
Lung Combined chemoradiotherapy in stage
IIIA4/IIIB (numerator: combined
chemoradiotherapy in NSCLC primary cases
in stage IIIA4/IIIB with ECOG 0/1; population:
NSCLC primary cases in stage IIIA4/IIIB
No target in
2015
– 39.6% Annual Report of Certified Lung
Cancer Centers 2016 — Quality
Indicators (in German)
doi:10.13140/RG.2.1.3998.6327
Skin Malignant melanoma: sentinel-node biopsy
(SNB, numerator: primary cases in which
SNB was carried out; population: primary
cases of primary cutaneous melanoma with
a tumor thickness of ≥1 mm and no evi-
dence of locoregional or distant metastasis)
≥ 80% 72.7% (32/44) 85.2% Annual Report of Certified Skin
Cancer Centers 2016 — Quality
Indicators (in German)
doi:10.13140/RG.2.1.2227.2408
Ovary Postoperative chemotherapy for advanced
ovarian carcinoma (numerator: primary
surgical cases of FIGO IIB–IV ovarian
carcinoma with postoperative
chemotherapy; population: primary surgical




– 96.4% Annual Report of Certified
Gynecological Cancer Centers 2016
— Quality Indicators (in German)
doi:10.13140/RG.2.1.1052.0568
Cervix Histological confirmation No target in
2015
– 100.0% Annual Report of Certified
Gynecological Cancer Centers 2016




Imaging in patients with oral cavity
carcinoma to determine N category
(numerator: patients with CT or MRI
examinations of the region from the cranial
base to the superior thoracic aperture to
determine the N category; population:




– 91.7% Annual Report of Certified Head and





Interdisciplinary case discussions (numerator:
primary cases [elective patients: pre-
interventional, emergency patients: post-
interventional] presented at the tumor con-
ference; population: primary cases), indicator
not derived from clinical guidelines
≥ 95% 68.4% (13/19) 96.4% Annual Report of Certified Neuro-
Oncological Tumor Centers 2016 —
Quality Indicators (in German)
doi:10.13140/RG.2.1.2788.7609
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OncoBox that can interact with and extract data from
the tumor documentation softwares used in Germany,
runs a plausibility check of the data and calculates the
quality indicators. Discrepancies are fed back to the cen-
ters for clearance. Cancer type and also center–specific
results regarding the quality indicators are presented to
the public in annual reports (e.g., [25]) and in scientific
journals (e.g., [20, 26, 27]). Some of the requirements
and quality indicators are the same for all center types
and tumor entities, such as a study participation rate of
5% of patients, delivery of social services and psycho-
oncological counseling to all patients, and discussion of
all patients in specific multidisciplinary boards. However,
most of the requirements are tailored to the specific
center/tumor. As an example, one tumor-specific quality
indicator for each center type is listed in Table 2. The
quality indicators presented in the Table are derived
from the clinical guidelines, unless otherwise indicated,
and are part of the annual reports.
With the number of DKG certified centers outside
Germany constantly increasing, the German Cancer
Society’s certification system has now become the largest
in Europe. This provides many opportunities, including
the ability to compare the quality of care not only within
different regions of one country, but also across coun-
tries. Smaller countries with only a few centers, which
would otherwise lack an appropriate comparator, can
match their results with many centers from different
countries and evaluate their development over time.
Acquiring the certificate: The center perspective
The certification criteria are outlined on the website of
the independent certification institute OnkoZert
(www.onkozert.de). Once a center has decided to apply
for its initial certificate, it submits an inquiry form 3 to
6 months prior to the projected audit date. The inquiry
form is reviewed by OnkoZert and a judgement is made
on whether the center is in principle suitable for certifi-
cation or whether its current structures make certifica-
tion impossible. It is recommended that the centers then
submit the necessary data 2 months prior to the audit
date. The documents are formally reviewed and passed
on to the responsible auditor(s), who provide(s) a
written assessment about the contents. This assessment
is then sent to the centers so that they can use it to
make final adjustments regarding structures and
processes. The subsequent on-site audit takes one or
two days, depending on the type of audit, and includes
auditing of all departments that shall participate in the
certified center as well as of external cooperation
partners. Relevant documents such as patient charts are
reviewed on site and compared with the data submitted.
Discrepancies between the actual situation and the
certification criteria must be corrected within 3 months
after the audit and are then re-evaluated by the auditor
on paper or on site, depending on the specific issue. The
auditor submits the audit report to OnkoZert, which
verifies the data, and passes the audit report on to the
Certificate Award Committee. Finally, the latter decides
on denying or awarding of the certificate, which is then
valid for 3 years. Full reevaluation-audits take place
every 3 years, and surveillance audits — i.e., shorter
audits focusing on the results for key figures and quality
indicators are performed every year.
Conclusions
The DKG Cancer Center Certification program is a
unique program: It is entirely voluntary, covers the most
relevant tumor entities in a steadily increasing propor-
tion, is based on guidelines of the highest quality, is run
by experts in the field independent of governmental in-
fluence and comprises the whole spectrum of cancer
care from prevention to screening, multidisciplinary
treatment, social and psychooncological, supportive and
palliative care. By implementing guidelines of the highest
quality and the best available medical knowledge into
everyday care it aims at comprehensively improving the
quality of cancer care across all relevant tumor entities
and across all regions. An important goal of the program
is to also make quality of care transparent across all sites
and thereby allowing to compare the centers based on
Table 2 Example quality indicators for each center/module type (Continued)
Center/
module
Quality indicator definition Target value Sites meeting the
target in 2015
Median Source
Pancreas Lymph-node examination (numerator:
primary surgical cases of pancreas with ≥10
regional lymph nodes in the surgical
specimen after completion of surgical
treatment; population: primary surgical cases
in pancreas (OPS 5–524 ff., 5–525 ff. only




– 90.0% Annual Report of Certified Neuro-
Oncological Tumor Centers 2016 —
Quality Indicators (in German)
doi:10.13140/RG.2.1.2788.7609
CT, computed tomography; DCIS, ductal carcinoma in situ; DOI, digital object identifier; FIGO, Fédération Internationale de Gynécologie et d’Obstetrique; ICD,
International Statistical Classification of Diseases and Health-Related Problems, 10th Revision; MRI, magnetic resonance imaging; NSCLC, non–small cell lung
cancer; PSA, prostate-specific antigen; TME, total mesorectal excision
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objective indicators. This shall in turn stimulate mutual
learning among the participating certified units.
The certification program has led to several paradigm
shifts in Germany. Only three shall be outlined here.
First and foremost, multidisciplinarity in cancer care has
become widely established and is not limited to the
multidisciplinary tumor boards. This is a development
that would not have been foreseeable 15 years ago. The
way in which the individual patient is treated no longer
depends on one clinician alone, but includes expertise
from the relevant providers within the network, who are
specified by name. This multidisciplinary approach is
not limited to medical specialties, but also includes
psycho-social care [28] as well as nursing and palliative
care, to which every patient is entitled. Secondly, the
“separation of powers” in the certification system facili-
tates fair processes for the development and evaluation
of requirements and for awarding certificates. Specific
professional groups cannot play a dominant role.
Thirdly, the collection and reporting of quality-of-care
data that are implemented throughout the certification
program [27], makes provider evaluation indicator-based
and allows to compare the results and enables mutual
learning. Indeed, due to the success of this program,
comparisons are not limited to one country, but also in-
clude centers in other countries including Switzerland,
Austria, and Italy. This provides an opportunity to make
the quality of cancer care comparable on a European
scale and to expand collaborations on this topic between
scientific societies in different countries.
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